Strategy for quantifying trace levels of BMAA in cyanobacteria by LC/MS/MS
- 966 Downloads
The cyanobacterial neurotoxin β-N-methylamino-l-alanine (BMAA) is an amino acid that is putatively associated with the pathology of amyotrophic lateral sclerosis/Parkinsonism–dementia complex (ALS-PDC) disease. It raises serious health risk concerns since cyanobacteria are ubiquitous thus making human exposure almost inevitable. The identification and quantification of BMAA in cyanobacteria is challenging because it is present only in trace amounts and occurs alongside structurally similar compounds such as BMAA isomers. This work describes an enhanced liquid chromatography/tandem mass spectrometry platform that can distinguish BMAA from its isomers β-amino-N-methyl-alanine, N-(2-aminoethyl) glycine (AEG), and 2,4-diaminobutyric acid, thus ensuring confident identification of BMAA. The method's sensitivity was improved fourfold by a post-column addition of acetonitrile. The instrument and method limits of detection were shown to be 4.2 fmol/injection (or 0.5 pg/one column) and 0.1 μg/g dry weight of cyanobacteria, respectively. The quantification method uses synthesized deuterated BMAA as an internal standard and exhibits good linearity, accuracy, and precision. Matrix effects were also investigated, revealing an ion enhancement of around 18 %. A lab-cultured cyanobacterial sample (Leptolyngbya PCC73110) was analyzed and shown to contain about 0.73 μg/g dry weight BMAA. The isomer AEG, whose chromatographic properties closely resemble those of BMAA, was also detected. These results highlight the importance of distinguishing BMAA from its isomers for reliable identification as well as providing a sensitive and accurate quantification method for measuring trace levels of BMAA in cyanobacterial samples.
KeywordsALS-PDC Isomers AEG BMAA Post-column addition Matrix effect
We thank Prof. Birgitta Bergman and Dr. Johan Eriksson (Department of Botany, Stockholm University) for providing the samples used in this study.
- 4.Mulder DW, Kurland LT (1987) Motor neuron disease: epidemiologic studies. Adv Exp Med Biol 209:325Google Scholar
- 6.Spencer PS (1987) Guam ALS/parkinsonism-dementia: a long-latency neurotoxic disorder caused by “slow toxin(s)” in food? Can J Neurol Sci 14:347Google Scholar
- 20.Esterhuizen M, Downing T (2008) beta-N-methylamino-l-alanine (BMAA) in novel South African cyanobacterial isolates. Ecotoxicol Environ, 71(2):309–313Google Scholar
- 21.Esterhuizen-Londt M, Downing S, Downing TG (2011) Improved sensitivity using liquid chromatography mass spectrometry (LC-MS) for detection of propyl chloroformate derivatised beta-N-methylamino-l-alanine (BMAA) in cyanobacteria. Water SA 37:133Google Scholar
- 36.Snyder LR, Cruz-Aguado R, Sadilek M, Galasko D, Shaw CA, Montine TJ (2009) Parkinson-dementia complex and development of a new stable isotope dilution assay for BMAA detection in tissue. Toxicol Appl Pharmacol 240:180Google Scholar
- 43.Li A, Fan H, Ma F, McCarron P, Thomas K, Tang X, Quilliam MA (2012) Elucidation of matrix effects and performance of solid-phase extraction for LC-MS/MS analysis of beta-N-methylamino-l-alanine (BMAA) and 2,4-diaminobutyric acid (DAB) neurotoxins in cyanobacteria. Analyst 137:1210 (Cambridge, UK)CrossRefGoogle Scholar
- 44.Banack SA, Metcalf JS, Jiang L, Craighead D, Ilag LL, Cox PA (2012) Cyanobacteria produce N-(2-aminoethyl)glycine, a backbone for peptide nucleic acids which may have been the first genetic molecules for life on earth. PLoS One 7:e49043Google Scholar